SK pharmteco, 저분자 의약품·펩타이드 생산능력 확대 위해 미국에 2억 달러 이상 투자 추진

SK pharmteco announced a comprehensive plan to invest more than $200 million over the next five years to expand and upgrade its U.S. development and manufacturing infrastructure for small-molecule drugs and peptides. The investment is intended to build a more resilient supply chain and meet unprecedented demand from a broad customer base, strengthening the company’s U.S. biopharma manufacturing capacity.